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On November 27, 2013, President
Obama signed into law the Drug Qual-
ity and Security Act ("DQSA"),
which amends the Federal Food, Drug,
and Cosmetic Act ("FDCA") to add
statutory provisions addressing drug
compounding and supply chain issues.
This article discusses Title I of this leg-
islation, known as the Compounding
Quality Act, and draft compounding
guidances subsequently issued by
the Food and Drug Administration
("FDA"). Section I provides a brief his-
tory of FDA's regulation of compounding
activities before the Compounding
Quality Act's enactment. Section II
reviews the Compounding Quality Act
and FDA's new draft guidances. Section
III considers some of the questions left
unanswered by the new legislation.




The FDCA gives FDA broad
statutory authority to regulate the
manufacture of new drugs, a category
that also includes most biologics.'
Section 50 5 (a) of the statute prohibits
the introduction of unapproved new
drugs into interstate commerce. Under
the FDCA, a "new drug" is a drug "the
composition of which is such that such
drug is not generally recognized... as
safe and effective" for the uses pre-
scribed, recommended, or suggested in
its labeling. Once FDA approves either
the new drug application ("NDA") or
biologics license application ("BLA")
for a new drug, the manufacture of that
drug is subject to FDA regulations.
FDA considers drug manufacturing to
include a broad scope of activities and
defines the term "manufacturing" to
include the "making" of a drug "by
chemical, physical, biological, or other
procedures."' In addition to the premar-
ket approval required for a new drug, the
agency imposes substantial additional
obligations on drug manufacturers,
including registration,4 compliance with
current good manufacturing practices
("GMPs"),' submission to establishment
inspection,6 and product labeling
requirements.
The traditional compounding of
drugs, also known as pharmacy com-
pounding, is the process by which drug
ingredients are combined, mixed, or
altered by a pharmacy in order to cre-
ate a medication that is designed to
meet an individual patient's needs.'
This process is understood as "traditional"
continued on page 3
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compounding because it is a compo-
nent of traditional pharmacy practice,9
one that allows patients to obtain
medically viable alternatives when
they cannot take a prescription medi-
cine in its commercially available
form. Classic examples of pharmacy
compounding include a medication
compounded for a patient who is aller-
gic to an ingredient in a commercially
available product, or a medication
whose dosage has been diluted for a
pediatric patient.'o Traditional phar-
macy compounding is distinct from a
practice known as "large-scale com-
pounding." Large-scale compounders,
also referred to as "outsourcing facili-
ties," produce large quantities of drugs,
through compounding, without indi-
vidual patient prescriptions.
Compounding - whether con-
ducted in a pharmacy for individual
patients or in an outsourcing facility
on a large-scale basis - implicates the
new drug approval provisions of the
FDCA. In particular, compounded
drugs constitute "new drugs" under
the FDCA's definition of the term
because they are not generally recog-
nized as safe and effective (nor have
their safety and effectiveness been ver-
ified). Because compounded drugs
constitute "new drugs" and lack
approved NDAs, the manufacture and
marketing of compounded drugs con-
stitute the manufacture and marketing
of unapproved new drugs.
Although FDA clearly has author-
ity to proceed against the shipment of
unapproved new drugs, it takes the
general position that it does not regu-
late either the practice of pharmacy or
the practice of medicine, which fall
within the purview of the states." This
fact, combined with the lack of
explicit provisions in the statute
addressing compounding per se, has
complicated FDA's efforts in this area.
FDA has historically exercised
enforcement discretion with respect to
traditional pharmacy compounding,
recognizing the "important public
health function" served by "meeting
the specialized needs of individual
patients for whom commercially avail-
able approved drugs are inadequate or
inappropriate." 2 Although pharmacies
are still subject to FDA's general prohi-
bitions against the adulteration of
drugs" and false or misleading drug
labeling," they are largely exempt
from the agency's broad statutory
inspection authority under what is
known as the "pharmacy exemption."
A pharmacy qualifies for this exemp-
tion if it complies with state law,
dispenses drugs upon prescription, and
does not "through a subsidiary or other-
wise, manufacture.. .drugs or devices
for sale other than in the regular course
[of its retail pharmacy business].""
FDA has not exercised the same
enforcement discretion for large-scale
compounding facilities. The agency
has openly focused its enforcement
efforts on "establishments that produce
large quantities of unapproved new
drugs under the guise of traditional
compounding, and establishments
whose activities result in significant
violations of the new drug, adultera-
tion, or misbranding violations of the
FDCA."'6 To reinforce the distinction
between permissible and impermissible
compounding, FDA issued a Compli-
ance Policy Guide ("CPG") in 1992
that listed factors the agency would
consider when determining whether a
pharmacy operated outside the scope
of traditional compounding practice.1
This CPG remained in effect until
Congress enacted the Food and Drug
Administration Modernization Act of
1997 ("FDAMA"), which amended
the FDCA to add section 503A. This
statutory provision created a safe
harbor for traditional pharmacy com-
pounding, which had previously
existed under FDA's "pharmacy
exemption," and codified FDA's frame-
work set out in the 1992 CPG for
identifying impermissible, non-tradi-
tional compounding activities.
Volume 26, Number 4, April 2014
FDA's Unclear Enforcement
Authority Under Western States
The complex regulatory land-
scape for compounding that set the
stage for the DQSA stems in large
part from legal uncertainty surround-
ing section 503A. Section 503A
included restrictions on the solicita-
tion and advertisement of pharmacy
compounding services.' In Western
States Medical Center v. Shalala, a group
of pharmacies challenged section
503A(c) - and a Nevada federal dis-
trict court agreed - as infringing their
constitutional right to free speech.19
The Ninth Circuit Court of Appeals
affirmed the Nevada court's decision
but also held that the speech restric-
tions were non-severable, thus
invalidating section 503A as a whole.20
Several years later, the Fifth Circuit
Court of Appeals arrived at the oppo-
site conclusion and held in Medical
Center Pharmacy v. Mukasey that the
solicitation and advertising provisions,
although unconstitutional under the
First Amendment, were severable from
the rest of section 503A.21
In 2002, after the Ninth Circuit's
decision in Western States invalidating
all of section 503A but before the
split with the Fifth Circuit emerged
in the Medical Center Pharmacy deci-
sion, FDA issued a revised CPO
articulating its policy on the practice
of pharmacy compounding.2 2 The
agency's policy remained similar in
most respects to section 503A, with
the notable exception of the solicita-
tion and advertising restrictions
struck down as unconstitutional. In a
departure from FDA's enforcement
policy before the Western States deci-
sion, the revised CPG no longer
considered solicitation or advertising
to be one of the factors that would
trigger FDA enforcement action.
Nevertheless, the 2002 CPG, like
previous FDA statements, reiterated
the agency's commitment to targeting
compounding establishments
continued on page 4
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"engaged in manufacturing and dis-
tributing unapproved new drugs for
human use in a manner that is clearly
outside the bounds of traditional
pharmacy practice and that violates
the [FDCA]."2 3
After the Fifth Circuit's Medical
Center Pharmacy decision revived sec-
tion 503A, however, FDA's own
position on compounding was split.
The agency announced that it was
"evaluating" the Fifth Circuit's opin-
ion but, in the meantime, would
"follow the court's decision in the
Fifth Circuit and with respect to the
plaintiffs covered by the decision.""
Therefore, for large-scale compound-
ers located within the Fifth Circuit's
jurisdiction, FDA would base its regu-
latory authority on section 503A,
with the advertising and solicitation
restrictions severed from the statute.
In other jurisdictions, the agency
would "continue to follow the
enforcement approach reflected in
the [revised 2002 CPG]."25 Before the
recent legislative activity surrounding
compounding, however, FDA issued
no official policy statements regarding
how the agency would resolve the cir-
cuit split and approach enforcement
actions brought against compounders.
The Compounding Quality
Act and FDA Compounding
Draft Guidance Documents
The Compounding Quality Act
marks the culmination of legislative
efforts initiated in the wake of the
meningitis outbreak in October 2012
that resulted in 48 deaths, stemming
from a product compounded by the
New England Compounding Center
("NECC").26 Although members of
Congress blamed FDA for not regu-
lating NECC more closely, FDA
Commissioner Margaret Hamburg
contended in hearings before House
and Senate committees that confusion
existed about whether FDA or state
4
authorities held responsibility for regu-
lating such compounding facilities."
Compounding Quality Act
The Compounding Quality Act
addresses the controversy surrounding
compounding by amending the FDCA
in two ways: (1) codifying the distinc-
tion between traditional and
non-traditional compounding by
establishing a category of "outsourcing
facilities" subject to a new statutory
scheme at the compounder's option;"
and (2) removing the unconstitutional
restrictions on solicitation and adver-
tising in section 503A, thus resolving
the circuit split over severability."
Under the new section 503B of
the FDCA,3 0 a compounder may vol-
untarily subject itself to FDA
regulation by registering with the
agency as an outsourcing facility. An
"outsourcing facility" is "a facility at
one geographic location or address
that is engaged in the compounding
of sterile drugs; has elected to register
as an outsourcing facility; and com-
plies with all of the requirements [in
section 503B]."3 ' An outsourcing
facility need not have a pharmacy
license, and it may compound without
prescriptions for individual patients.32
If a compounder elects to register
with FDA as an outsourcing facility, it
is exempt from the FDCA require-
ments relating to NDA approval3
and supply chain," as well as the
requirement that the labeling of the
drugs that it ships bear adequate
directions for use,3 5 as long as it satis-
fies the conditions set out in section
503B. Unlike traditional pharmacy
compounders who satisfy the condi-
tions in section 503A, however,
outsourcing facilities are not exempt
from OMP requirements. Outsourcing
facilities must also comply with
annual registration,36 regular report-
ing,3 7 and adverse event reporting38
requirements, and they are subject to
FDA inspection.39
Section 503B also spells out stan-
dards for materials that may be
compounded at registered outsourcing
facilities. Like traditional pharmacy
compounders, outsourcing facilities may
not compound drugs that are "essen-
tially a copy of one or more approved
drugs"40 or that present "demonstrable
difficulties" for compounding.4 The
statute also imposes conditions on the
compounding of bulk substances,
although the standard for outsourcing
facilities is more stringent than that for
traditional pharmacy compounders.42
Both sections 503A and 503B rely on
FDA to establish lists of accepted bulk
substances and drugs presenting demon-
strable difficulties for compounding.43
The Compounding Quality Act
establishes a system of "enhanced
communication" between state boards
of pharmacy and FDA, which is a
novel development." The House floor
debate suggests that, by making this
provision mandatory, Congress hoped
to encourage "meaningful communica-
tion" 4 5 between FDA and state boards
of pharmacy as a way to "remedy one
of the major problems that surfaced in
the NECC situation - a lack of effec-
tive communication between State
boards of pharmacy and the FDA."46
Section 105 of the statute contem-
plates that state boards of pharmacy
will report to the Secretary of Health
and Human Services enforcement
actions taken against compounding
pharmacies and other "concerns that a
compounding pharmacy may be acting
contrary to section 503A."4 7 FDA
must notify state boards of pharmacy
when it receives notice of a state
enforcement action against a com-
pounding pharmacy and whenever it
determines that a pharmacy is in viola-
tion of section 503A."
FDA Compounding Draft
Guidance Documents
Within days of the Compounding
Quality Act's enactment, FDA released
three draft guidance documents relating
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to the statute. Although these docu-
ments address procedural (rather than
substantive) issues, this quick publica-
tion reflects the seriousness with
which the agency views its role in the
regulation of drug compounding.
Pharmacy Compounding of Human
Drug Products Under Section 503A"
The first draft guidance applies to
traditional pharmacy compounding
regulated under section 503A of the
FDCA, rather than to the outsourc-
ing facilities newly recognized under
the Compounding Quality Act. Like
the new statute, however, this draft
guidance ties up loose ends left by the
circuit split over section 503A by
withdrawing the 1998 and 2002
CPGs related to compounding."o The
draft guidance also reiterates FDA's
expectation that state boards of phar-
macy will continue their oversight
and regulation of the practice of phar-
macy, including traditional pharmacy
compounding."
As for FDA's own enforcement
actions, the draft guidance indicates
that the agency "expects to employ a
risk-based enforcement approach,"
under which "the highest enforce-
ment priority" will be given to
compounded drugs and violations
posing "the greatest public health
risks."" The draft guidance explains
that enforcement actions may be
brought against pharmacy compound-
ing regulated under section 503A for
violations such as misbranding or the
production of adulterated or unap-
proved new drugs.5 3
Interim Product Reporting Under
Section 503B and Registration
Under Section 503B55
FDA's second draft guidance
addresses the reporting requirement
that applies to outsourcing facilities
that have elected to register under
section 503B. The agency indicates in
this draft guidance that it encourages
establishments intending to operate
as outsourcing facilities to register
with FDA "immediately."" According
to the draft guidance, if a facility regis-
ters before June 2, 2014, the agency
does not intend to enforce the initial
registration reporting requirement set
out in section 503B "immediately," as
long as the facility submits its report
within two months of the initial regis-
tration.5 1 In its third draft compounding
guidance, FDA outlines the criteria and
requirements for outsourcing facilities
to register on a voluntary basis under
section 503B.
Discussion
Many have praised the new statu-
tory provisions as enhancing FDA
oversight of non-traditional com-
pounders through express authority to
impose GMP and adverse event
reporting requirements, among other
things. A better reading, however,
might be that it undermines FDA's
authority. Not only is the registration
scheme voluntary, but FDA had
authority over non-traditional com-
pounding under section 505 before
Congress enacted the statute. Indeed,
the agency's actions in connection
with the meningitis outbreak linked
to compounding by NECC proves the
point. Arguably, the net effect of this
law is to remove regulatory tools (such
as the NDA requirement) from FDA's
arsenal with respect to large-scale
compounding businesses.
Not surprisingly, much of the
regulated industry, i.e., those subject
to rigorous NDAs and abbreviated
new drug applications ("ANDAs"),
opposed the creation of a separate and
less-regulated "outsourcing facility"
category.5 ' Moreover, Commissioner
Hamburg commented in early Decem-
ber that the scheme "does not provide
FDA with all the additional authori-
ties sought."" Further, some concerns
articulated by the Government
Accountability Office ("GAO") in
July 2013 - prior to enactment -
remain valid. These include the fact
that outsourcing facilities may hold
themselves out as "FDA-registered,"
which could confuse consumers and
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physicians about the extent of over-
sight of the facilities (in particular,
lead to inferences of FDA approval).
The GAO also noted the lack of con-
sistent oversight across all 50 states,
which may continue to be an issue,
because the Compounding Quality
Act assumes - but does not guarantee
- significant state participation in the
regulatory scheme.60 Two points thus
emerge. First, many stakeholders
sought something more than (or dif-
ferent from) what was ultimately
enacted. Second, the fact that the
statute arguably weakens FDA's
authority in this very important pub-
lic health area may not have been
fully appreciated by all stakeholders.
One important question that
stakeholders have raised since
enactment is whether and how
non-traditional (large-scale) com-
pounders will be persuaded to register
voluntarily for FDA oversight under
the new scheme.' There are at least
two possibilities. First, some have spec-
ulated that payors (such as hospitals)
will require large scale compounding
facilities to register with FDA.62 FDA
is reported to be "pushing hard" for
hospitals to buy drugs compounded by
facilities that have registered with the
agency." Other than these market-
type forces, another possibility is the
use of payment policies (i.e., limiting
reimbursement to compounded drugs
from registered facilities).64 Of course,
the fact that registration effectively
provides a safe harbor from enforce-
ment action under section 505 (the
NDA requirement) may also be per-
suasive. Comments from some
interstate compounding facilities that
they might register in order to elimi-
nate uncertainty over who oversees
them are off the mark, because there
was no question prior to the statute
that all compounding constitutes
manufacture of a new drug and that
large enterprises were squarely within
FDA's jurisdiction.
FDA's substantial outreach
efforts in the short time since the
Compounding Quality Act's
continued on page 6
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enactment show that the agency views
the initial phase of outsourcing facility
registration as a critical moment for
the new statute. The agency has
already sent letters to governors,
health departments, boards of phar-
macy, and hospital purchasers asking
that they help FDA encourage large-
scale compounders to register.65 FDA
has also contacted hospitals to pledge
the agency's strict oversight of regis-
tered facilities and launched an online
database that identifies registered out-
sourcing facilities.66 As of early March,
this list includes 33 facilities, although
a few of the registered facilities are dif-
ferent locations of the same outsourcing
conglomerate. Whether and to what
extent large-scale facilities will con-
tinue to register remains an important
question and could ultimately prompt
new legislation, particularly if FDA oth-
erwise lacks sufficient resources for
enforcement actions against those who
do not register.
Perhaps the most important inter-
pretive question is what constitutes a
copy of an approved drug. The Com-
pounding Quality Act defines the term
"essentially a copy of an approved
drug" as, among other things, "a drug
that is identical or nearly identical to
an approved drug,"67 unless the
approved drug appears on the drug
shortage list in effect under section
506E of the FDCA. This is consistent
with administrative use of the phrase
in FDA's 2002 CPO, prior to the stat-
ute's enactment.66 For instance, the
agency's 2006 warning letter to the
NECC cited the facility's manufacture
of trypan blue ophthalmic solution
and 20 percent aminolevulinic acid
solution, both of which were commer-
cially available." According to the
warning letter, the compounded ver-
sions of these solutions constituted
copies of commercially available
drugs.70 The agency's interpretation of
"essentially a copy" will draw an impor-
tant line for enforcement purposes. At
the very least, this phrase should be
6
interpreted to mean that large-scale
compounding must not be a way of
obtaining a "generic" version of an
innovator product that still has patent
protection or data exclusivity. This
would circumvent intellectual property
rights, thereby seriously undermining
incentives to innovate in medicine and
therefore ultimately harm patients in
need of new medicines.
Various other questions and
implementation tasks remain open. For
instance, recent press reports suggest
FDA is developing a memorandum of
understanding for use with the states,
which would in some fashion limit
interstate shipment of compounded
drugs.' It remains to be seen how the
state boards of pharmacy will react, or
how "meaningful" the "enhanced
communications" between federal and
state governments will be. The agency
will soon need to clarify the manufac-
turing requirements that apply to
outsourcing facilities. Answers to these
and other outstanding questions may
be forthcoming this year, as FDA repre-
sentatives have indicated that the
agency considers compounding to be a
priority and will be "moving aggres-
sively forward" to implement the
Compounding Quality Act.n The
agency has made good on its promise by
issuing warning letters to two outsourc-
ing facilities for manufacturing
unapproved new drugs that were also
misbranded because the facilities did
not receive individual prescriptions for
these drugs."
Conclusion
The Compounding Quality Act
was enacted as a way to regulate
large-scale compounders like the
NECC, which operate largely in the
shadows of the prescription drug mar-
ket. On balance, however, the new
statute does not provide FDA the
additional authority that it sought and
that the innovator and generic
industries supported. There are also
very important questions about
whether the registration program will
be used and, if not, whether FDA will
be able to effectively oversee (and
institute enforcement action against)
large-scale compounders who operate
outside the voluntary scheme. If
another public health crisis like the
meningitis outbreak linked to NECC
occurs, stakeholders will likely return
to Congress for additional legislation.
Congress must regularly re-authorize
FDA's ability to collect fees from new
drug applicants,74 and the upcoming
round of negotiations leading to reau-
thorization in 2017 may provide a
suitable opportunity for revisiting the
issues.
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